ADMA - Overview: Asymmetric Dimethylarginine, Plasma
Assessing the likelihood of future coronary events in patients with coronary heart disease, type II diabetes mellitus, or kidney disease Prompting intervention and assessing improvements among subjects with elevated ADMA and...
CACR3 - Overview: Calcium/Creatinine Ratio, Random, Urine
Evaluation of calcium oxalate and calcium phosphate kidney stone risk Calculation of urinary supersaturation Evaluation of bone diseases, including osteoporosis and osteomalacia
PBU - Overview: Lead, 24 Hour, Urine
Detecting clinically significant lead exposure in 24-hour specimens This test is not a substitute for blood lead screening.
B6PA - Overview: Pyridoxic Acid, Plasma
Determining the concentration of pyridoxic acid in the assessment of vitamin B6 status
AFSH - Overview: Alpha Follicle Stimulating Hormone Immunostain, Technical Component Only
May aid in the classification of pituitary adenomas
C8FX - Overview: C8 Complement, Functional, Serum
Diagnosis of C8 deficiency Investigation of a patient with an undetectable total hemolytic complement level
CYSQN - Overview: Cystinuria Profile, Quantitative, 24 Hour, Urine
Diagnosis of cystinuria using 24-hour urine collections
C6FX - Overview: C6 Complement, Functional, Serum
Diagnosis of C6 deficiency Investigation of a patient with an undetectable total complement level
CRT24 - Overview: Creatinine, 24 Hour, Urine
Urinary creatinine, in conjunction with serum creatinine, is used to calculate the creatinine clearance, a measure of renal function Normalizing urinary analytes to account for the variation in urinary concentration
Mayo Clinic Ranked No. 1 Hospital Nationwide by U.S. News & World Report - Insights
Report’s 29th annual "Best Hospitals Honor Roll" published online on August 14. Mayo Clinic also ranked No. 1 in more specialties than any other hospital in the country....
NELL-1 [Test in Focus] - Insights
D., discusses how Mayo Clinic Laboratories’ new immunohistochemistry test for the detection of NELL-1 antigen, a biomarker for membranous nephropathy found in 10% to 15% of patients, provides diagnostic...
Looking Back on Clinical Chemistry 1 - Insights
in the Mayo Clinic Medical Laboratory Science program, takes a look back on her Clinical Chemistry 1 course....
Detection of (1→3)-𝝱-D-glucan as a Marker of Invasive Fungal Disease - Insights
In this month’s “Hot Topic,” Elitza Theel, Ph.D., will discuss the detection of (1→3)-β-D-glucan (BDG) in serum as a biomarker for the presence of invasive fungal infections....
Orexin-A/Hypocretin-1 for the Diagnosis of Type 1 Narcolepsy [Test in Focus] - Insights
test to perform as well as to interpret. The orexin-A/hypocretin-1 test is a sensitive and specific alternative to the MSLT to diagnose type 1 narcolepsy....